DELISTING ALERT
Notice of a Decision under Section 18 – 19 and Section 21 of the Health (Pricing and Supply of Medical Goods) Act 2013
With effect from 1st April 2017 and in accordance with Section 18 – 19 and Section 21 of The Health (Pricing and Supply of Medical Goods) Act 2013 the HSE will remove from the list of reimbursable items the following PDE5 inhibitors (used to treat erectile dysfunction). The decision applies to be both branded and parallel imported products. The decision does NOT apply to formulations reimbursed under the High Tech arrangements for other indications. Reimbursement of PDE5 inhibitors for treatment of erectile dysfunction will be restricted to low cost Reference Priced Sildenafil. PDE5 products that will not be reimbursed under GMS and Community Drug Schemes from 1st April 2017 are:
- Tadalafil Cialis Tabs. 10 mg. (4)
- Tadalafil Cialis Tabs. 20 mg. (4)
- Vardenafil Levitra Tabs. 10 mg. (4)
- Vardenafil Levitra Tabs. 20 mg. (4)
- Vardenafil Levitra Tabs. 5 mg. (4)
Source: PCRS Monthly Product Update - February 2017 (PDF)